The estimated Net Worth of Physics & Chemistry Laborat... is at least $336 Million dollars as of 11 December 2018. Physics Laborat owns over 133,915 units of Amphastar Pharmaceuticals Inc stock worth over $330,258,493 and over the last 9 years Physics sold AMPH stock worth over $5,351,184.
Physics has made over 4 trades of the Amphastar Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Physics sold 133,915 units of AMPH stock worth $2,851,050 on 11 December 2018.
The largest trade Physics's ever made was selling 133,915 units of Amphastar Pharmaceuticals Inc stock on 11 December 2018 worth over $2,851,050. On average, Physics trades about 75,979 units every 277 days since 2015. As of 11 December 2018 Physics still owns at least 7,327,679 units of Amphastar Pharmaceuticals Inc stock.
You can see the complete history of Physics Laborat stock trades at the bottom of the page.
Physics's mailing address filed with the SEC is 11570 6th St, Rancho Cucamonga, CA 91730, USA.
Over the last 10 years, insiders at Amphastar Pharmaceuticals Inc have traded over $72,457,295 worth of Amphastar Pharmaceuticals Inc stock and bought 66,100 units worth $921,987 . The most active insiders traders include Jack Y.Luo Mary Z. Zhang, Richard K Prins, and William J Peters. On average, Amphastar Pharmaceuticals Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,459,051. The most recent stock trade was executed by Floyd F. Petersen on 5 September 2024, trading 3,000 units of AMPH stock currently worth $139,410.
amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int
Amphastar Pharmaceuticals Inc executives and other stock owners filed with the SEC include: